文献速递头颈部肿瘤放疗放疗物理与技术

基于个体化剂量模型优化鼻咽癌放疗后甲状腺功能减退的管理:多中心回顾性分析

Transforming the management of radiotherapy-induced hypothyroidism in nasopharyngeal carcinoma through an Innovative individualized radiation dosage model: A multicenter retrospective analysis.
PubMed 文献 · Radiother Oncol · 2025-05-21

该多中心回顾性研究纳入621例鼻咽癌患者,分为训练队列和两个外部验证队列,利用二元逻辑回归和Cox方法拟合匹配临床特征的耐受剂量,提出TSH-体积指数(TVI)新参数并构建RIHT预测参数VStd。结果显示基于TVI的VStd预测性能优于经典NTCP和机器学习模型,并开发了基于TVI的甲状腺剂量处方表。

要点

  • TVI联合EUD是RIHT的独立预后因素。
  • 基于TVI的VStd预测性能优于VS40、VS45、VS50、NTCP及机器学习模型。
  • 开发了基于TVI的甲状腺剂量处方表以提升临床适用性。

核心结论

  • 研究开发了鼻咽癌放疗中个体化甲状腺给药的髙精度模型,并配有临床相关表格以实现定制化甲状腺保护。

研究设计与样本

  • 多中心回顾性分析纳入四个癌症中心的621例鼻咽癌患者,数据分为训练队列和两个外部验证队列。
  • 采用二元逻辑回归和时依Cox方法在训练队列中拟合匹配临床特征的耐受剂量值。
  • 引入TSH-体积指数(TVI)作为新参数,并基于耐受剂量下甲状腺受保护体积(VStd)构建RIHT参数。
  • 使用AUC和C-index比较VStd与经典NTCP模型及机器学习模型的预测性能。

主要发现

  • 训练队列2年和3年RIHT发生率分别为27.7%和35.3%,外部验证队列1分别为30.0%和41.5%,外部验证队列2分别为27.2%和38.0%。
  • 单因素分析识别性别、等效均匀剂量(EUD)、甲状腺体积(TV)、TSH和TVI为RIHT预测因素,多因素分析确认EUD和TVI为独立预后因素。
  • 基于TVI的VStd参数在预测性能上优于VS40、VS45、VS50指数、经典NTCP模型及机器学习模型。
  • 三个队列随访期分别为28个月(范围1-66)、33.5个月(范围3-82)和17个月(范围2-56)。

关键数值与推荐

  • 基于TVI的甲状腺剂量处方表已开发用于临床个体化给药。

临床怎么用

  • 临床可利用基于TVI的甲状腺剂量处方表,在鼻咽癌放疗中实现个体化甲状腺保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current guidelines for thyroid radiation dose prescription lack uniformity and fail to consider the unique characteristics of individual patients. This study aimed to develop an individualized thyroid dosing regimen to enhance thyroid protection during radiotherapy. METHODS AND MATERIALS: In this study, we enrolled 621 patients with nasopharyngeal carcinoma (NPC) across four distinct cancer centers, stratifying the data into a training cohort and two external validation cohorts. The specific clinical characteristic-matched tolerated dose values were fitted using binary logistic regression and time-to-event Cox methods in the training cohort. The TSH-volume index (TVI), calculated as thyroid-stimulating hormone (TSH) level divided by thyroid volume (TV), was introduced as a novel parameter. A radiation-induced hypothyroidism (RIHT) parameter was developed using the volume of thyroid spared at the tolerated dose (VStd) and compared with classical normal tissue complication probability (NTCP) and machine learning models using the area under the curve (AUC) and concordance index (C-index). RESULTS: The follow-up periods spanned 28 (range, 1-66), 33.5 (range, 3-82), and 17 months (range, 2-56), respectively, across these cohorts. RIHT was observed in 27.7 % and 35.3 % of patients at 2 and 3 years in the training cohort, respectively; 30.0 % and 41.5 % in the external validation cohort 1; and 27.2 % and 38.0 % in the external validation cohort 2. Univariable analysis identifies sex, equivalent uniform dose (EUD), TV, TSH, and the TVI as predictors of RIHT, while multivariable analysis confirms EUD and TVI as independent prognostic factors. The TVI-based VStd parameter outperformed the VS40, VS45, and VS50 indices (representing volumes spared at 40 Gy, 45 Gy, and 50 Gy, respectively), classical NTCP models, and even machine learning models in predictive performance. To enhance clinical applicability, we have developed a thyroid dose prescription table based on TVI. CONCLUSIONS: We developed a high-accuracy model for individualized thyroid dosing in NPC radiotherapy. The model, supported by a clinically relevant table, offers a customized approach to thyroid protection, enhancing both predictive accuracy and clinical utility.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ding J, Yin X, Lin Y, et al. Transforming the management of radiotherapy-induced hypothyroidism in nasopharyngeal carcinoma through an Innovative individualized radiation dosage model: A multicenter retrospective analysis. Radiother Oncol. 2025. PMID: 40409363. doi:10.1016/j.radonc.2025.110943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。